ICOTF Stock, Ico Therapeutics Inc Information

iCo Therapeutics in licenses and redefines existing drug candidates or generics by employing reformulation and delivery technologies for new or expanded use indications. The Company holds worldwide rights to an oral drug delivery platform, with Oral Amphotericin B Amp B as the initial platform candidate, utilizing a known anti fungal drug to treat life threatening infectious diseases. iCo also has worldwide rights to iCo , a monoclonal antibody targeting eotaxin . With Phase clinical history, Bertilimumab iCo is candidate for the treatment of vernal or atopic keratoconjunctivitis. iCo is in Phase clinical studies with iCo s partner, Immune Pharmaceuticals.